Synthesis of new conjugated mesomeric betaines from alkoxycarbonylazinium salts

A new series of conjugated mesomeric betaines have been synthesized from the reaction of various aminoheterocycles with 2-methylthio-4-oxo-3-phenylpyrido[2,1-φ][1,2,4]triazinium iodide, itself prepared from 2-ethoxycarbonylpyridinium N-aminide. Some of the heterobetaines and salts obtained have been studied by 1H-NMR, and their structures have been confirmed by X-ray analysis. The crystal structures reveal unexpected complementary stabilizing interactions between some betaines and their salts.We wish to express our thanks to the Comisió Interdepartamental de Reçerca i Innovació Tecnológica (CIRIT) for financial support (Project QFN94-4619) and to the Ministerio de Educación y Ciencia for a grant to one of us (JVM)

COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study

Mortality rates for COVID-19 have declined over time in the general population, but data in patients with hematologic malignancies are contradictory. We identified independent prognostic factors for COVID-19 severity and survival in unvaccinated patients with hematologic malignancies, compared mortality rates over time and versus non-cancer inpatients, and investigated post COVID-19 condition. Data were analyzed from 1166 consecutive, eligible patients with hematologic malignancies from the population-based HEMATO-MADRID registry, Spain, with COVID-19 prior to vaccination roll-out, stratified into early (February–June 2020; n = 769 (66%)) and later (July 2020–February 2021; n = 397 (34%)) cohorts. Propensity-score matched non-cancer patients were identified from the SEMI-COVID registry. A lower proportion of patients were hospitalized in the later waves (54.2%) compared to the earlier (88.6%), OR 0.15, 95%CI 0.11–0.20. The proportion of hospitalized patients admitted to the ICU was higher in the later cohort (103/215, 47.9%) compared with the early cohort (170/681, 25.0%, 2.77; 2.01–3.82). The reduced 30-day mortality between early and later cohorts of non-cancer inpatients (29.6% vs. 12.6%, OR 0.34; 0.22–0.53) was not paralleled in inpatients with hematologic malignancies (32.3% vs. 34.8%, OR 1.12; 0.81–1.5). Among evaluable patients, 27.3% had post COVID-19 condition. These findings will help inform evidence-based preventive and therapeutic strategies for patients with hematologic malignancies and COVID-19 diagnosis.Depto. de MedicinaFac. de MedicinaTRUEFundación Madrileña de Hematología y HemoterapiaFundación Leucemia y LinfomaAsociación Madrileña de Hematología y Hemoterapiapu

Ocio y tiempo libre

El objetivo es ofrecer información sobre alternativas de ocio relacionadas con el deporte, medio ambiente, pintura, fotografía, literatura, fiestas de disfraces, bailes y patinaje. Se pretende, así, fomentar la capacidad creativa y el contacto con el medio ambiente. Entre las actividades destacan representaciones dramáticas, charlas medioambientales, excursiones al campo, concursos de pintura, fotografía y relato breve. La evaluación del proyecto se basa en reuniones mensuales del profesorado y encuestas a profesores y alumnos.Madrid (Comunidad Autónoma). Consejería de Sanidad y Servicios SocialesMadridNo disponibleES

De libro en libro descubriendo el mundo

Esta experiencia consiste, básicamente, en recoger investigaciones realizadas por los alumnos, producciones literarias, recopilaciones de aportaciones de las familias o ilustraciones de textos y se realizan libros que posteriormente pasan a formar parte de los fondos de la biblioteca del centro. Se pretende sistematizar la producción de libros y permitir aprovechar al máximo las posibilidades educativas que ofrecen los diferentes tipos de textos así como las diferentes técnicas de ilustración. Los objetivos son fomentar la lectura y la escritura, hacer más significativas las actividades de lectoescritura, desarrollar la capacidad creadora en el alumnado y motivarles para que suman un papel activo en la producción de cultura. Con motivo de una salida para recoger moras y hacer mermelada, se realiza el libro Las Moras; también se recogen canciones dibujos y adivinanzas sobre el otoño; se hace una recopilación de recetas; uno sobre el carnaval; y sobre diferentes obras de teatro que se representan en el centro. Adjunta CD-ROM con los materiales elaborados por los alumnos.Madrid (Comunidad Autónoma). Consejería de Educación. Dirección General de Ordenación AcadémicaMadridMadrid (Comunidad Autónoma). Subdirección General de Formación del Profesorado. CRIF Las Acacias; General Ricardos 179 - 28025 Madrid; Tel. + 34915250893ES

Synthesis and biological evaluation of 2,6-di-tert-butylphenol hydrazones as 5-lipoxygenase inhibitors

The preparation of hydrazone derivatives of 3,5-di-tert-butyl-4-hydroxybenzaldehyde and the inhibition of 5-lipoxygenase (5-LO) by these compounds is discussed

Historia-historias de la lectura : XXIV Jornadas de Estudios Históricos Locales - XVII Jornadas de Historia de la Educación de los Países de Lengua Catalan

En el título, los términos 'Història' e 'Històries' están separados por una barra inclinadaLa temática de las jornadas se centra en el análisis de la dimensión educativa de la lectura a lo largo de la historia, y se desarrolla alrededor de los siguientes ejes temáticos: enseñar y aprender a leer; espacios y contextos para la lectura y su fomento; las lecturas educativas y la lectura y la educación como a elementos de debate y reflexión.La temàtica de les jornades se centra en l'anàlisi de la dimensió educativa de la lectura al llarg de la història, i es desenvolupa al voltant dels eixos temàtics següents: ensenyar i aprendre a llegir; espais i contextos per a la lectura i el seu foment; les lectures educatives i la lectura i l'educació com a elements de debat i reflexió.BalearesUniversitat de les Illes Balears. Redined Balears; Edifici Guillem Cifre de Colonya. Ctra. de Valldemossa, Km 7,5; 07122 Palma de Mallorca; +34971172792; +34971173190; [email protected]

Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trialResearch in context

Summary: Background: Anti-COVID-19 hyperimmune immunoglobulin (hIG) can provide standardized and controlled antibody content. Data from controlled clinical trials using hIG for the prevention or treatment of COVID-19 outpatients have not been reported. We assessed the safety and efficacy of subcutaneous anti-COVID-19 hyperimmune immunoglobulin 20% (C19-IG20%) compared to placebo in preventing development of symptomatic COVID-19 in asymptomatic individuals with SARS-CoV-2 infection. Methods: We did a multicentre, randomized, double-blind, placebo-controlled trial, in asymptomatic unvaccinated adults (≥18 years of age) with confirmed SARS-CoV-2 infection within 5 days between April 28 and December 27, 2021. Participants were randomly assigned (1:1:1) to receive a blinded subcutaneous infusion of 10 mL with 1 g or 2 g of C19-IG20%, or an equivalent volume of saline as placebo. The primary endpoint was the proportion of participants who remained asymptomatic through day 14 after infusion. Secondary endpoints included the proportion of individuals who required oxygen supplementation, any medically attended visit, hospitalisation, or ICU, and viral load reduction and viral clearance in nasopharyngeal swabs. Safety was assessed as the proportion of patients with adverse events. The trial was terminated early due to a lack of potential benefit in the target population in a planned interim analysis conducted in December 2021. ClinicalTrials.gov registry: NCT04847141. Findings: 461 individuals (mean age 39.6 years [SD 12.8]) were randomized and received the intervention within a mean of 3.1 (SD 1.27) days from a positive SARS-CoV-2 test. In the prespecified modified intention-to-treat analysis that included only participants who received a subcutaneous infusion, the primary outcome occurred in 59.9% (91/152) of participants receiving 1 g C19-IG20%, 64.7% (99/153) receiving 2 g, and 63.5% (99/156) receiving placebo (difference in proportions 1 g C19-IG20% vs. placebo, −3.6%; 95% CI -14.6% to 7.3%, p = 0.53; 2 g C19-IG20% vs placebo, 1.1%; −9.6% to 11.9%, p = 0.85). None of the secondary clinical efficacy endpoints or virological endpoints were significantly different between study groups. Adverse event rate was similar between groups, and no severe or life-threatening adverse events related to investigational product infusion were reported. Interpretation: Our findings suggested that administration of subcutaneous human hyperimmune immunoglobulin C19-IG20% to asymptomatic individuals with SARS-CoV-2 infection was safe but did not prevent development of symptomatic COVID-19. Funding: Grifols

Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period

The objective of this work is to analyze the survival of infliximab, etanercept and adalimumab in patients who have switched among tumor necrosis factor (TNF) antagonists for the treatment of chronic arthritis. BIOBADASER is a national registry of patients with different forms of chronic arthritis who are treated with biologics. Using this registry, we have analyzed patient switching of TNF antagonists. The cumulative discontinuation rate was calculated using the actuarial method. The log-rank test was used to compare survival curves, and Cox regression models were used to assess independent factors associated with discontinuing medication. Between February 2000 and September 2004, 4,706 patients were registered in BIOBADASER, of whom 68% had rheumatoid arthritis, 11% ankylosing spondylitis, 10% psoriatic arthritis, and 11% other forms of chronic arthritis. One- and two-year drug survival rates of the TNF antagonist were 0.83 and 0.75, respectively. There were 488 patients treated with more than one TNF antagonist. In this situation, survival of the second TNF antagonist decreased to 0.68 and 0.60 at 1 and 2 years, respectively. Survival was better in patients replacing the first TNF antagonist because of adverse events (hazard ratio (HR) for discontinuation 0.55 (95% confidence interval (CI), 0.34-0.84)), and worse in patients older than 60 years (HR 1.10 (95% CI 0.97-2.49)) or who were treated with infliximab (HR 3.22 (95% CI 2.13-4.87)). In summary, in patients who require continuous therapy and have failed to respond to a TNF antagonist, replacement with a different TNF antagonist may be of use under certain situations. This issue will deserve continuous reassessment with the arrival of new medications. © 2006 Gomez-Reino and Loreto Carmona; licensee BioMed Central Ltd